Digital Pathology and AI: Now and in 2025
Experts Nathan Buchbinder and Julianna Ianni discuss digital pathology and AI trends in 2024—and what the next year may hold
Experts Nathan Buchbinder and Julianna Ianni discuss digital pathology and AI trends in 2024—and what the next year may hold
Carl Icahn has decided to take his beef with Illumina’s board of directors over the acquisition directly to company shareholders.
The deal closed Feb.22, but the FTC has expressed concerns about the acquisition and Amazon’s business practices in general.
Economic volatility and uncertainty is also making a significant impact on merger and acquisition activity in the diagnostics space.
The total market for PCR products will likely top $5 billion in 2023, according to a new report.
M&A activity in the clinical diagnostics space was significantly down in 2022 in terms of both deal volume and deal value.
The recent FDA approval of an OTC test shows that COVID-19 saliva testing may be poised for bigger and better things in the years ahead.
Though only seven transactions were announced or closed in November, two were billion-dollar deals.
Increasing incidences of heart disease, as well as technological advances, will drive growth over the next eight to 10 years, reports say.
Continuing recent patterns, M&A deal-making in the diagnostics space was low in volume but high in impact in October.
While the overall M&A market has been slow in 2022, Labcorp has been on a bit of an acquisitions binge.